EN DE
Watch Kura Oncology Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Kura Oncology Inc (KURA) fair value: what the stock is really worth

As of Nov 16, 2026: fair value (intrinsic value) of Kura Oncology Inc stock $4.79, price $7.09, that is 32.4% below the price, quality 28 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US50127T1097

KO Kura Oncology Inc logo Thin data Nov 14, 2026

Kura Oncology Inc

KURA · US

Expensive (fair value 32% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Mixed Growth (revenue YoY +25.2 %/yr in USD) 
Insiders bought $3.9M (6M) · sold $2.7M 
Fair value $4.79 · Overvalued 
Quality 28/100 
Falling price (downtrend) 
Negative free cash flow 
Trails peers (2/8) 
Narrow moat 16/100
Recent news very negative 
Thin data 
Estimate
Watch Kura Oncology Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$23.53 $5.54 Fair Value $4.79 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

60‑month range $5.54 – $23.53 · fair‑value band $3.59 – $5.99 · the $7.09 price screens above the $4.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Kura Oncology in your weekly email

Every Wednesday you see whether Kura Oncology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer.

Show moreShow less

The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors.

The company is headquartered in San Diego, California.

Stock analysis

Kura Oncology Inc (KURA) currently trades at $7.09, while our estimate is $4.79, 32% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $3.59 (bear) to $5.99 (bull), the price of $7.09 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 28/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Kura Oncology Inc reported revenue of $67.5M in FY2025 versus $0 in FY2021. Reported net income was −$279M in FY2025.

Key figures

Market cap $630M Small · P/S ratio 8.71 · EPS (TTM) $−3.30 · Return on equity −225% · Return on assets (EBIT) −31.7% (5-year average) · Operating margin −394% · Revenue (TTM) $79.3M · Revenue growth (YoY) +10.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 16 out of 100 (medium confidence).

What moves the price

The share trades about 48% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −32%, KURA screens richer than that median.

Fair Value

Bear $3.59 Fair Value $4.79 Bull $5.99
Price $7.09 · Downside -32.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 28/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 3
How much profit the company makes from its sales and capital
Quality Growth 42
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 47
Debt, balance sheet and risk of trouble
Investment 57
Does it invest with discipline instead of growing at any price?
Low Volatility 49
How calm the share price moves, does not count
Price momentum 10
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 39
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $3.9M, on Nov 16, 2026. Over the same period, 6 people sold shares worth $2.7M.

  • BuyTroy Edward WilsonPresident and CEO, Director3× since Aug 17, 2026: 400,000 shares, avg. $9.64$3.9MNov 16, 2026
  • SaleBrian T. PowlChief Commercial Officer5× since Jan 27, 2026: 53,548 shares, avg. $10.53$564,109Sep 29, 2026
  • SaleMollie LeoniChief Medical Officer3× since Jan 27, 2026: 134,359 shares, avg. $10.00$1.3MSep 29, 2026
  • SaleKathleen FordChief Operating Officer3× since Jan 27, 2026: 14,644 shares, avg. $10.09$147,776Sep 29, 2026
  • SaleThomas James DoyleSVP, Finance & Accounting2× since Jan 27, 2026: 11,749 shares, avg. $9.26$108,795Sep 28, 2026
  • SaleTeresa Brophy BairChief Legal Officer4× since Jan 27, 2026: 53,393 shares, avg. $11.28$602,303Sep 28, 2026
  • SaleFrancis BurrowsChief Scientific Officer3× since Dec 18, 2025: 45,763 shares, avg. $10.22$467,594Sep 24, 2026
  • SaleFaheem HasnainDirector10,000 shares at $10.98$109,800Dec 9, 202510b5-1 plan

Plus one other filing such as a grant, option exercise or tax withholding. It is not a market purchase or sale.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 26/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

KURA screens overvalued: fair value 32% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (82 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Very negative
Recent news coverage is unusually downbeat.

Compare Kura Oncology Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 847 stocks

Beats the industry median on 2/7 measures
Overall it trails its industry peers.
Valuation
Quality Score 28 · Bottom 25%
Fair Value upside −32.4% · Below median
Profitability
Return on assets −37.7% · Below median
Growth and dividend
Revenue growth (quarter YoY) 10.1% · Above median
Balance sheet
Debt / equity 0.06× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 3.62× · Pricier than median
P/S (12 months) 7.95× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)51 · sector 36
PAST (return on equity)0 · sector 0
HEALTH (low debt)97 · sector 96
DIVIDEND (yield)0 · sector 21

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs KURA
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs KURA
Samsung Biologics Co 207940 1,423,000 KRW 1,552,100 KRW +9% vs KURA
argenx SE ARGX $950.95 $908.40 −4% vs KURA
CSL Limited CSL A$199.55 A$186.49 −7% vs KURA
Moderna, Inc MRNA $215.27 $135.64 −37% vs KURA
BeOne Medicines AG 6160 HK$249.40 HK$152.92 −39% vs KURA
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs KURA
Celltrion, Inc 068270 214,500 KRW 74,945 KRW −65% vs KURA
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs KURA

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kura Oncology Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Kura Oncology Inc Fair Value". https://www.fairvalue-calculator.com/stock/KURA

Frequently asked questions

Is Kura Oncology Inc (KURA) overvalued or undervalued?
As of Nov 14, 2026, our estimate of fair value is $4.79 versus a price of $7.09, about 32% lower (overvalued).
What is the fair value of KURA?
Our estimate for Kura Oncology Inc is $4.79 (as of Nov 14, 2026), built from audited fundamentals. The current price: $7.09.
What is the quality score of KURA?
Kura Oncology Inc has a Quality Score of 28/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kura Oncology Inc (KURA)?
Our calculated price target is the estimate of $4.79 (as of Nov 14, 2026). Cautious scenario $3.59, optimistic scenario $5.99. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Kura Oncology Inc stock forecast for 2026?
Our estimate puts fair value at $4.79, about 32% lower versus a price of $7.09 (overvalued). Cautious scenario $3.59, optimistic scenario $5.99. The calculation is refreshed regularly with new filings.
What is the revenue of Kura Oncology Inc (KURA)?
Kura Oncology Inc reported trailing-twelve-month revenue of about $79.3M (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of Kura Oncology Inc (KURA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kura Oncology Inc it is $4.79 per share (as of Nov 14, 2026), against a price of $7.09.
Is Kura Oncology Inc stock overvalued or undervalued in 2026?
As of Nov 14, 2026, KURA trades above its calculated fair value: price $7.09, fair value $4.79, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KURA?
No. The price is what the market pays today ($7.09); the fair value is what the company's own numbers justify ($4.79). For Kura Oncology Inc the two are $2.30 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kura Oncology Inc worth?
The market values Kura Oncology Inc at about $630M (market capitalisation, as of Nov 14, 2026). Per share that is $7.09; our models calculate a fair value of $4.79 per share.
What do the bullish and bearish scenarios say about KURA?
Our models span a range for Kura Oncology Inc: cautious scenario $3.59, base $4.79, optimistic $5.99 per share (as of Nov 14, 2026, price $7.09). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kura Oncology Inc (KURA)?
Balance-sheet figures for Kura Oncology Inc (as of Nov 14, 2026): return on equity −224.9%, debt of 0.06 per unit of equity. They feed the Quality Score of 28/100, which measures business quality independently of the share price.
How far is KURA from its 52-week high?
Kura Oncology Inc trades at $7.09, about 48% below its 52-week high of $13.59 and 4% above the low of $6.80 (as of Nov 16, 2026). Distance from the high says nothing about value: that is what the fair value of $4.79 is for.
Which stocks are comparable to Kura Oncology Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kura Oncology Inc stock attractive at the current price?
The data as of Nov 14, 2026: price $7.09, calculated fair value $4.79 (−32%), Quality Score 28/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Kura Oncology Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kura Oncology Inc (KURA)?
The closing price on Nov 16, 2026 was $7.09. Our estimate is $4.79, about 32% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kura Oncology Inc right now?
The price sits above even our optimistic bull case ($5.99). The favourable scenario is already priced in. Weak quality (28/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Kura Oncology Inc

How large is the market capitalisation of Kura Oncology Inc (KURA)?
The market capitalisation of Kura Oncology Inc is $630M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kura Oncology Inc (KURA)?
The price-to-sales ratio of Kura Oncology Inc is 8.71 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kura Oncology Inc (KURA)?
Earnings per share at Kura Oncology Inc are $−3.30. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Kura Oncology Inc (KURA)?
The return on equity (ROE) of Kura Oncology Inc is −225% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kura Oncology Inc (KURA)?
On an EBIT basis the return on assets of Kura Oncology Inc is −31.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kura Oncology Inc (KURA)?
The operating margin of Kura Oncology Inc is −394% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kura Oncology Inc (KURA)?
Revenue at Kura Oncology Inc is growing 10.1% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Kura Oncology Inc (KURA) generate?
The free cash flow of Kura Oncology Inc is −$70.7M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Kura Oncology Inc (KURA) hold?
Kura Oncology Inc holds more cash than debt, $129M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Kura Oncology Inc in the live analysis

One click puts Kura Oncology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.